Free shipping on all orders over $ 500

Preladenant

Cat. No. M9345

All AbMole products are for research use only, cannot be used for human consumption.

Preladenant Structure
Synonym:

SCH-420814

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
1mg USD 33  USD33 In stock
2mg USD 47  USD47 In stock
5mg USD 75  USD75 In stock
10mg USD 125  USD125 In stock
25mg USD 217  USD217 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Preladenant is a potent and competitive antagonist of the human adenosine A2A receptor with a Ki of 1.1 nM. Preladenant also completely antagonizes cAMP in cells expressing the recombinant human A2A receptor.

Preladenant (1 mg/kg) inhibits L-Dopa-induced behavioral sensitization after repeated daily administration, which suggests a reduced risk of the development of dyskinesias. Preladenant exhibits antidepressant-like profiles in models of behavioral despair, namely the mouse tail suspension test and the mouse and rat forced swim test. Preladenant produces a dose-dependent reduction in parkinsonian scores at doses of 1 mg/kg (min score: 9.0) and 3 mg/kg (min score: 6.5). A subthreshold dose of Preladenant reduces minimum and mean parkinsonian scores in animals treated with 3 mg kg of L-Dopa to 5.25 and 6.88 respectively. A Wilcoxin test is used to compare individual treatments against vehicle. Preladenant (3 mg/kg), L-Dopa (3, 6, and 12 mg/kg), and the combination of Preladenant and L-Dopa (1 or 3 mg/kg+3 mg/kg) are all significantly improved on the minimum parkinsonian score. In addition, both the 12 mg/kg L-Dopa and L-Dopa+Preladenant groups are significantly improved on both minimum and mean parkinsonian scores relative to the 3 mg/kg L-Dopa group.

Chemical Information
Molecular Weight 503.56
Formula C25H29N9O3
CAS Number 377727-87-2
Solubility (25°C) DMSO 2.5 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Nobutaka Hattori, et al. Adjunctive preladenant: A placebo-controlled, dose-finding study in Japanese patients with Parkinson's disease

[2] Robert A Hauser, et al. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned

[3] Z Wang, et al. Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation

[4] Robert A Hauser, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

[5] John D Salamone. Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders

Related Adenosine Receptor Products
CV1808

CV1808 (2-Phenylaminoadenosine) is a non-selective A2 adenosine receptor (A2 AR) agonist with Kis of 76 and 1450 nM for A2A and A3 adenosine receptor subtypes, respectively.

FK 453 

FK 453 is a potent and selective adenosine A1 receptor antagonist with an IC50 value of 17.2 nM.

GS-9667

GS-9667 (CVT 3619), a novel N6-5'-substituted adenosine analog, is a selective, partial agonist of the A1 adenosine receptor (A1AdoR).

PD81723 

PD81723 is an adenosine receptor binding enhancer.

PSB-0788 

PSB-0788 is a new selective high-affinity A2B antagonist with IC50 value of 3.64 nM and Ki value of 0.393 nM, respeactively.

  Catalog
Abmole Inhibitor Catalog




Keywords: Preladenant, SCH-420814 supplier, Adenosine Receptor, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.